Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 12/20 | 0.50 |
| ▸ | CNR1 | P21554 | 6/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891808 | 0.89 | ALDH1A1 (0.67) | ALDH1A1CNR2CNR1MAPK14RAF1 | |
| SCHEMBL14693072 | 0.88 | ALDH1A1 (0.50) | ALDH1A1CNR2CNR1MAPK14RAF1 | |
| SCHEMBL13413814 | 0.84 | ALDH1A1 (0.50) | ALDH1A1CNR2CNR1MAPK14RAF1 | |
| SCHEMBL9891815 | 0.84 | CNR2 (0.54) | ALDH1A1CNR2CNR1MAPK14 | |
| SCHEMBL12566646 | 0.84 | ALDH1A1 (0.50) | ALDH1A1CNR2CNR1MAPK14RAF1 | |
| SCHEMBL9891929 | 0.84 | EPHX2 (0.51) | ALDH1A1CNR2CNR1MAPK14 | |
| SCHEMBL14647434 | 0.83 | ALDH1A1 (0.55) | ALDH1A1CNR2CNR1MAPK14RAF1 | |
| SCHEMBL12543529 | 0.82 | CNR2 (0.57) | ALDH1A1CNR2CNR1MAPK14RAF1 | |
| SCHEMBL13413823 | 0.82 | ALDH1A1 (0.48) | ALDH1A1CNR2CNR1MAPK14RAF1 | |
| SCHEMBL9891817 | 0.81 | CNR2 (0.56) | ALDH1A1CNR2CNR1MAPK14RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362039-B2 | Therapeutic uses of compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-29 | — | — | US | disclosed |
| US-8362039-B2 | Therapeutic uses of compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-29 | — | — | US | disclosed |
| US-8349871-B2 | Therapeutic uses of compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-08 | — | — | US | disclosed |
| US-20120010184-A1 | Therapeutic Uses of Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-12 | — | — | US | disclosed |
| US-20120010184-A1 | Therapeutic Uses of Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-12 | — | — | US | disclosed |
| US-20110312932-A1 | Therapeutic Uses of Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312932-A1 | Therapeutic Uses of Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-8048899-B2 | Compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-8048899-B2 | Compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20100081644-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081644-A1 | Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ALDH1A1 2112/4885CNR2 1/4885CNR1 2/4885 |
| US-20110312932-A1 | Therapeutic Uses of Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ALDH1A1 1813/4885CNR2 1/4885CNR1 2/4885 |
| US-20120010184-A1 | Therapeutic Uses of Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ALDH1A1 1813/4885CNR2 1/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.